3 good short squeeze candidates:

MannKind Corp. (MNKD) $2.69 up $0.12 (4.67%).

According to an SEC filing on July 03, 2012, MannKind had two insiders combine to purchase a total of 31,251,054 shares at a total value of $77,189,555.

MannKind has had well documented issues with its Afrezza inhalation powder, an ultra rapid-acting insulin formulation designed to be inhaled by the user. In January 2011, the FDA issued a complete response letter (CRL) to MannKind for its new drug application (NDA) for Afrezza inhalation powder to treat patients suffering from type 1 and type 2 diabetes for the control of hyperglycemia.

In its CRL, the FDA showed its concern regarding the use of the in-vitro performance data and clinical pharmacology data to bridge MannKind's next generation inhaler to the Phase 3 trials conducted using its MedTone inhaler. In other words, it appeared Mannkind used a different inhaler in the clinical testing, submitted that data, then sought approval for a totally different inhaler.

Those who I have talked to who are close to this situation have informed me that MannKind has now resolved these issues, and should gain approval on Afrezza this time around. Being short in MannKind is foolish at this time, in my strong opinion.

http://seekingalpha.com/article/704631-1-monster-short-squeeze-candidate-3-good-ones-1-to-stay-away-from